The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Xiaotuan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affilia…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, beta-Lactamases, Ceftazidime. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Scientific Research Project of Department of Education of Zhejiang Province of China.
Abstract (Originalsprache)
Objectives
To investigate the prevalence and mechanisms of ceftazidime/avibactam heteroresistance in KPC-producing Klebsiella pneumoniae (KPC-KP) isolates, as well as the role of heteroresistance in the transition of ceftazidime/avibactam susceptibility to resistance.
Methods
Clinical KPC-KP isolates were obtained from a tertiary hospital in China from 2016 to 2017 and 2019 to 2020. Antimicrobial susceptibility was determined by the broth microdilution method. Population analysis profiles were used to assess ceftazidime/avibactam heteroresistance. WGS and molecular cloning were conducted to reveal heteroresistance mechanisms and molecular characteristics.
Results
The findings indicated that the transition of ceftazidime/avibactam susceptibility to resistance during the treatment of KPC-KP infection is primarily attributed to the heteroresistance exhibited by KPC-KP isolates towards ceftazidime/avibactam. Among 355 ceftazidime/avibactam-susceptible KPC-KP isolates (indicating a resistance rate of 0%), 41 (11.55%) exhibited ceftazidime/avibactam heteroresistance, with the primary mechanism being the presence of KPC mutant subpopulations. These KPC variants, arising from point mutations, deletions and insertions, significantly increased ceftazidime/avibactam resistance while alongside enhanced carbapenem susceptibility. Notably, 11 new KPC variants were identified. Furthermore, four heteroresistant isolates were caused by mixed infection involving subpopulations carrying NDM-1 or NDM-5. Phylogenetic analysis indicated that the clonal spread of ST11-KL64 KPC-KP may be correlated with the prevalence of heteroresistance.
Conclusions
Ceftazidime/avibactam heteroresistance, primarily driven by pre-existing KPC variants, underscores the importance of considering heteroresistance in ceftazidime/avibactam therapeutics. Awareness of these dynamics is crucial for the effective and sustainable clinical application of ceftazidime/avibactam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province…
- Department of Medical Lab Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
ORCID-Profile: Xiaotuan Zhang, Tieli Zhou
Förderung
- Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province
- Scientific Research Project of Department of Education of Zhejiang Province of China
Zitieren
APA
Zhang, X., Zeng, W., Kong, J., Huang, Z., Shu, H., Tang, M., Qian, C., Xu, C., Zhou, T., & Ye, J. (2024). The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae174
Vancouver
Zhang X, Zeng W, Kong J, Huang Z, Shu H, Tang M, et al. The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae174
BibTeX
@article{Zhang2024,
author = {Zhang, Xiaotuan and Zeng, Weiliang and Kong, Jingchun and Huang, Zeyu and Shu, Hongyun and Tang, Miran and Qian, Changrui and Xu, Chunquan and Zhou, Tieli and Ye, Jianzhong},
title = {The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae174}
}
EUVIMED